Market Price

221.60 

3.80 1.7%

as of Aug 07 '20

52 Week Range:

95.58 221.64


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 20.88
12.18
11.04
12.46
13.81
14.16
15.08
18.33
21.55
25.99
31.31
growth rate -41.7% -9.4% 12.9% 10.8% 2.5% 6.5% 21.6% 17.6% 20.6% 20.5%
Earnings BIT 149.11
-334.08
132.66
129.75
138.33
191.86
230.06
273.13
313.06
342.63
367.10
growth rate -100.0% 100.0% -2.2% 6.6% 38.7% 19.9% 18.7% 14.6% 9.5% 7.1%
Avg.PE 19.92
-6.60
12.20
17.86
24.69
28.60
23.42
27.43
24.87
30.48
29.65
growth rate -100.0% 100.0% 46.4% 38.2% 15.8% -18.1% 17.1% -9.3% 22.6% -2.7%
ROA 5.24
-17.10
6.66
6.19
6.37
7.18
7.55
6.48
4.37
6.67
5.90
growth rate -100.0% 100.0% -7.1% 2.9% 12.7% 5.2% -14.2% -32.6% 52.6% -11.5%
ROE 8.89
-32.64
18.07
17.28
16.56
19.30
21.25
19.72
13.11
19.16
17.07
growth rate -100.0% 100.0% -4.4% -4.2% 16.6% 10.1% -7.2% -33.5% 46.2% -10.9%
ROIC 7.08
-19.32
11.05
9.80
9.19
9.77
10.52
9.45
6.61
10.71
9.08
growth rate -100.0% 100.0% -11.3% -6.2% 6.3% 7.7% -10.2% -30.1% 62.0% -15.2%
Cur. Ratio 2.38
2.13
1.96
1.42
2.24
2.05
1.79
1.52
1.78
1.61
1.44
growth rate -10.5% -8.0% -27.6% 57.8% -8.5% -12.7% -15.1% 17.1% -9.6% -10.6%
Quick Ratio 1.75
1.47
1.20
0.93
1.57
1.46
1.31
1.13
1.34
1.20
1.06
growth rate -16.0% -18.4% -22.5% 68.8% -7.0% -10.3% -13.7% 18.6% -10.5% -11.7%
Leverage 1.60
2.52
2.96
2.64
2.57
2.80
2.82
3.24
2.80
2.93
2.87
growth rate 57.5% 17.5% -10.8% -2.7% 9.0% 0.7% 14.9% -13.6% 4.6% -2.1%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 190.10
165.90
184.81
203.00
220.63
257.99
270.07
364.05
430.02
472.25
514.03
growth rate -12.7% 11.4% 9.8% 8.7% 16.9% 4.7% 34.8% 18.1% 9.8% 8.9%
Acct.Payable 130.31
123.38
146.94
33.82
36.68
68.49
77.84
66.25
111.50
growth rate -5.3% 19.1% -77.0% 8.5% 86.7% 13.7% -14.9% 68.3%
Cur.Assets 595.60
552.90
425.84
485.25
552.55
579.25
559.23
656.83
826.63
897.84
1,021.33
growth rate -7.2% -23.0% 14.0% 13.9% 4.8% -3.5% 17.5% 25.9% 8.6% 13.8%
Total Assets 2,204.10
1,733.40
1,558.32
1,586.34
1,632.76
1,870.58
2,068.50
2,711.80
2,929.92
3,855.88
4,692.79
growth rate -21.4% -10.1% 1.8% 2.9% 14.6% 10.6% 31.1% 8.0% 31.6% 21.7%
Cash 182.60
179.20
68.91
109.69
155.93
160.02
117.95
117.63
163.79
195.44
238.01
growth rate -1.9% -61.6% 59.2% 42.2% 2.6% -26.3% -0.3% 39.3% 19.3% 21.8%
Inventory 102.70
100.30
92.97
88.47
89.40
89.04
93.74
95.83
114.96
127.89
160.66
growth rate -2.3% -7.3% -4.8% 1.1% -0.4% 5.3% 2.2% 20.0% 11.3% 25.6%
Cur.Liabilities 249.80
259.80
216.80
342.25
247.03
294.69
311.76
429.59
463.50
558.22
710.18
growth rate 4.0% -16.6% 57.9% -27.8% 19.3% 5.8% 37.8% 7.9% 20.4% 27.2%
Liabilities 828.90
1,046.00
1,032.74
985.54
971.19
1,166.23
1,302.93
1,858.02
1,865.91
2,517.58
3,026.32
growth rate 26.2% -1.3% -4.6% -1.5% 20.1% 11.7% 42.6% 0.4% 34.9% 20.2%
LT Debt 457.40
670.30
703.19
527.14
642.35
716.64
814.24
1,180.50
1,086.22
1,610.55
1,822.14
growth rate 46.6% 4.9% -25.0% 21.9% 11.6% 13.6% 45.0% -8.0% 48.3% 13.1%
Equity 1,375.20
687.40
525.58
600.81
640.98
672.20
733.07
836.77
1,045.08
1,317.33
1,634.58
growth rate -50.0% -23.5% 14.3% 6.7% 4.9% 9.1% 14.2% 24.9% 26.1% 24.1%
Common Shares 66.00
63.00
51.00
48.00
48.00
48.00
48.00
48.00
49.00
49.00
50.00
growth rate -4.6% -19.1% -5.9% 0.0% 0.0% 0.0% 0.0% 2.1% 0.0% 2.0%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 79.85
42.86
49.14
47.53
39.15
56.93
63.25
55.29
82.43
140.05
140.51
growth rate -46.3% 14.7% -3.3% -17.6% 45.4% 11.1% -12.6% 49.1% 69.9% 0.3%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA 225.00
169.00
206.84
208.01
209.05
251.05
304.96
314.84
316.27
437.41
480.94
growth rate -24.9% 22.4% 0.6% 0.5% 20.1% 21.5% 3.2% 0.5% 38.3% 10.0%
FCF per Share 2.21
2.02
3.05
3.31
3.51
3.57
4.67
4.78
4.43
6.60
5.97
growth rate -8.6% 51.0% 8.5% 6.0% 1.7% 30.8% 2.4% -7.3% 49.0% -9.6%
Sale Purchase of Stock -263.17
-45.83
-72.14
73.69
39.37
23.20
38.87
growth rate 0.0% 0.0% 100.0% -46.6% -41.1% 67.6%
FCF 145.00
126.00
156.00
160.00
168.00
194.00
223.00
243.00
234.00
301.00
340.00
growth rate -13.1% 23.8% 2.6% 5.0% 15.5% 15.0% 9.0% -3.7% 28.6% 13.0%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 1,171.60
1,133.40
1,142.65
1,129.53
1,165.53
1,297.66
1,363.30
1,681.43
1,857.60
2,266.10
2,621.23
growth rate -3.3% 0.8% -1.2% 3.2% 11.3% 5.1% 23.3% 10.5% 22.0% 15.7%
Op.Income 169.60
-298.50
115.52
102.12
105.42
191.86
230.06
273.13
313.06
342.63
367.10
growth rate -100.0% 100.0% -11.6% 3.2% 82.0% 19.9% 18.7% 14.6% 9.5% 7.1%
IBT 151.60
-334.10
132.66
129.75
138.33
177.60
195.43
222.92
296.96
281.68
304.08
growth rate -100.0% 100.0% -2.2% 6.6% 28.4% 10.0% 14.1% 33.2% -5.1% 8.0%
Net Income 114.40
-336.70
115.52
102.12
105.42
126.70
149.31
154.77
123.36
226.37
252.02
growth rate -100.0% 100.0% -11.6% 3.2% 20.2% 17.9% 3.7% -20.3% 83.5% 11.3%
EPS 1.74
-5.38
2.14
2.01
2.12
2.66
3.13
3.23
2.54
4.62
5.07
growth rate -100.0% 100.0% -6.1% 5.5% 25.5% 17.7% 3.2% -21.4% 81.9% 9.7%
Gross Profit 423.00
384.80
402.24
392.08
394.90
476.00
533.66
658.10
721.87
842.69
965.03
growth rate -9.0% 4.5% -2.5% 0.7% 20.5% 12.1% 23.3% 9.7% 16.7% 14.5%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 81.23
95.21
119.54
93.88
growth rate 17.2% 25.6% -21.5%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 545.15
524.07
514.03
542.39
532.53
growth rate -3.9% -1.9% 5.5% -1.8%
Acct.Payable 99.38
107.23
111.50
102.70
82.98
growth rate 7.9% 4.0% -7.9% -19.2%
Cur.Assets 1,010.06
972.41
1,021.33
1,208.28
1,234.73
growth rate -3.7% 5.0% 18.3% 2.2%
Total Assets 4,625.48
4,582.56
4,692.79
5,201.79
5,240.88
growth rate -0.9% 2.4% 10.9% 0.8%
Cash 200.59
164.76
238.01
372.43
402.02
growth rate -17.9% 44.5% 56.5% 7.9%
Inventory 134.93
155.53
160.66
162.94
168.37
growth rate 15.3% 3.3% 1.4% 3.3%
Cur.Liabilities 635.60
681.65
710.18
690.90
727.94
growth rate 7.2% 4.2% -2.7% 5.4%
Liabilities 3,146.64
3,017.83
3,026.32
3,522.12
3,460.28
growth rate -4.1% 0.3% 16.4% -1.8%
LT Debt 2,012.12
1,855.88
1,822.14
2,300.89
growth rate -7.8% -1.8% 26.3%
Equity 1,455.07
1,532.31
1,634.58
1,651.98
1,752.64
growth rate 5.3% 6.7% 1.1% 6.1%
Common Shares 0.49
0.49
0.49
0.50
0.50
growth rate 0.2% -0.2% 1.4% 0.4%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 24.78
35.16
63.84
25.72
growth rate 41.9% 81.6% -59.7%
Cash Dividends
growth rate
Cash From OA 129.55
155.85
180.68
68.59
growth rate 20.3% 15.9% -62.0%
Sale Purchase of Stock
growth rate
FCF 104.77
120.68
116.84
42.87
growth rate 15.2% -3.2% -63.3%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 657.57
667.95
691.14
707.06
growth rate 1.6% 3.5% 2.3%
Op.Income 81.23
95.21
119.54
93.88
growth rate 17.2% 25.6% -21.5%
IBT 58.99
73.24
105.57
55.46
growth rate 24.1% 44.2% -47.5%
Net Income 43.73
72.81
80.35
50.77
growth rate 66.5% 10.4% -36.8%
EPS
growth rate
Gross Profit 238.83
246.73
266.27
252.54
growth rate 3.3% 7.9% -5.2%
R&D
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (90.33)

YOY Growth Grade:

C (54.37)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 43.17 44.52 26.11
EPS / Growth 15.4% 4.98 14.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 17.5%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 14.0% 15.6% 15.6%
Future PE 26.11 33.52 33.52
Future EPS 18.45 21.29 21.29
Value Price
MOS %
119.13
-46.2%
176.39
-20.4%
176.39
-20.4%
MOS Price 59.56 88.20 88.20
IRT 14.23 13.39 13.39

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.